Semisynthetic Maytansine analogues for the targeted treatment of cancer

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4392-4408

  Widdison, Wayne C ^a   Wilhelm, Sharon D ^a   Cavanagh, Emily E ^a   Whiteman, Kathleen R ^a   Leece, Barbara A ^a   Kovtun, Yelena ^a   Goldmacher, Victor S ^a   Xie, Hongsheng ^a   Steeves, Rita M ^a   Lutz, Robert J ^a   Zhao, Robert ^a   Wang, Lintao ^a   Blättler, Walter A ^a   Chari, Ravi V J ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFIDE; MAYTANSINE; MAYTANSINOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUC242 DM1; MONOCLONAL ANTIBODY HUC242 DM3; MONOCLONAL ANTIBODY HUC242 DM4; NATURAL PRODUCT; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISULFIDES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MAYTANSINE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33745847797     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060319f     Document Type: Article

References (24)

1. Kupchan, S. M.; Komoda, Y.; Court, W. A.; Thomas, G. J.; Smith, R. M.; Karim, A.; Gilmore, C. J.; Haltiwanger, R. C.; Bryan, R. F. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J. Am. Chem. Soc. 1972, 94, 1354-1356.
2. Kupchan, S. M.; Branfman, A. R.: Sneden, A. T.; Verma, A. K.; Dailey, R. G., Jr.; Komoda, Y.; Nagao, Y. Novel maytansinoids. Naturally occurring and synthetic antileukemic esters of maytansinol. J. Am. Chem. Soc. 1975, 97, 5294-5295.
3. Remillard, S.; Rebhun, L. I.; Howie, G. A.; Kupchan, S. M. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975, 189, 1002-1005.
4. Huang, A. B.; Lin, C. M.; Hamel, E. Maytansine inhibits nucleotide binding at the exchangeable site of tubulin. Biochem. Biophys. Res. Commun. 1985, 128, 1239-1246.
5. Kupchan, S. M.; Komoda, Y.; Branfman, A. R.; Sneden, A.T.; Court, W. A.; Thomas, G. J.; Hintz, H. P.; Smith, R. M.; Karim, A.; Howie, G. A.; Verma, A. K.; Nagao, Y.; Dailey, R. G., Jr.; Zimmerly, V. A.; Sumner, W. C., Jr.; The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J. Org. Chem. 1977, 42, 2349-2357.
6. Issell, B. F.; Crooke, S. T. Maytansine. Cancer Treat. Rev. 1978, 5, 199-207.
7. Sedlacek, H.-H.; Seemann, G.; Hoffmann, D.; Czech, J.; Lorenz, P.; Kolar, C.; Bosslet, K.; Antibodies as carriers of cytotoxicity. In Contributions to Oncology; Sedlacek, H.-H., et al., Eds.; Basel: New York, 1992; pp 1-145.
8. Xie, H.; Audette, C.; Hoffee, M.; Lambert, J. M.; Blättler, W. A. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J. Pharmacol. Exp. Ther. 2004, 310, 1073-1082.
9. Chari, R. V. J.; Martell, B. A.; Gross, J. L.; Cook, S. B.; Shah, S. A.: Blättler, W. A.; McKenzie, S. J.; Goldmacher, V. S. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992, 52, 127-131.
10. Liu, C.; Tadayoni, B. M.; Bourret, L. A.; Mattocks, K. M.; Derr, S. M.; Widdison, W. C.; Kedersha, N. L.; Ariniello, P. D.; Goldmacher, V. S.; Lambert, J. M.; Blättler, W. A.; Chari, R. V. J. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8618-8623.
11. Tolcher, A. W.; Ochoa, L.; Hammond, L. A.; Patnaik, A.; Edwards, T.; Takimoto, C.; Smith, L.; de Bono, J.; Schwartz, G.; Mays, T.; Jonak, Z.L.; Johnson, R.; DeWitte, M.; Martino, H.; Audette, C.; Maes, K.; Chari, R. V. J.; Lambert, J. M.; Rowinsky, E. K. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic. and biologic correlative study. J. Clin. Oncol. 2003, 21, 211-222
12. Helft, P. R.; Schilsky, R. L.; Hoke, F. J.; Williams, D.; Kindler, H. L.; Sprague, E.; DeWitte, M.; Martino, H. K.; Erickson, J.; Pandite, L.; Russo, M.; Lambert, J. M.; Howard, M.; Ratain, M. J. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin. Cancer Res. 2004, 10, 4363-4468.
13. Meister, A.; Anderson, M. E. Annu. Rev. Biochem. 1983, 52, 711-760.
14. Cassady, J. M.; Chan, K. K.; Floss, H. G.; Leistner, E. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) 2004, 52, 1-26.
15. Kupchan, S. M.; Sneden, A. T.; Branfman, A. R.; Howie, G. A.; Rebhun, L. I.; McIvor, W. E.; Wang, R. W.; Schnaitman, T. C. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J. Med. Chem. 1978, 21, 31-37.
16. Higashide, E.; Asai, M.; Ootsu, K.; Tanida, S.; Kozai, Y.; Hasegawa, T.; Kishi, T.; Sugino, Y.; Yoneda, M. Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. Nature 1977, 29, 721-722.
17. Asai, M.; Mizuta, E.; Izawa, M.; Haibaba, K.; Kishi, T. Isolation, chemical characterization and structure of ansamitocin, a new antitumor antibiotic. Tetrahedron 1978, 35, 1079-1085.
18. Kawai, A.; Akimoto, H.; Kozai, Y.; Ootsu, K.; Tanida, S.; Hashimoto, N.; Nomura, H. Chemical modification of ansamitocins. III. Synthesis and biological effects of 3-acyl esters of maytansinol. Chem. Pharm. Bull (Tokyo) 1984, 32, 3341-3351.
19. Kupchan, S. M.; Komoda, Y.; Branfman, A. R.; Dailey, R. G.; Zimmerly, V. A. Novel maytansinoids. Structural interrelations and requirements for antileukemic activity. J. Am. Chem. Soc. 1974, 96, 3706-3708.
20. Lindholm, L.; Holmgren, J.; Svennerholm, L.; Fredman, P.; Nilsson, O.; Persson, B.; Myrvold, H.; Lagergard, T. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int. Arch. Allergy Appl. Immunol. 1983, 71, 178-181.
21. Mickley, L. A.; Bates, S. E.; Richert, N. D.; Currier, S.; Tanaka, S.; Foss, F.; Rosen, N.; Fojo, A. T. Modulation of the expression of a multidrug resistance gene (mdr1/P-glycoprotein) by differentiating agents. J. Biol. Chem. 1989, 264, 18031-18040.
22. Goff, D. A.; Carroll, S. F. Substituted 2-iminothiolanes: Reagents for the preparation of disulfide cross-linked conjugates with increased stability. Bioconjugate Chem. 1990, 1, 381-386.
23. Goldmacher, V. S.; Tinnel, N. L.; Nelson, B. C. Evidence that pinocytosis in lymphoid cells has a low capacity. J. Cell Biol. 1986, 102, 1312-1319.
24. Goldmacher, V. S.; Anderson, J.; Blättler, W. A.; Lambert, J. M.; Senter, P. D. Antibody-complement-mediated cytotoxicity is enhanced by ribosome-inactivating proteins. J. Immunol. 1985, 135, 3648-3651.